
Exploring the Frontier of Multiomics: DeciBio Q&A with Peter Fromen, CEO of biomodal
A Q&A with Peter Fromen, CEO of biomodal, emphasising the potential applications of their technology, particularly in oncology, liquid biopsy, aging, and neurodegenerative disorders.